Effect of Magnesium Supplementation on Patients With Diabetic Nephropathy
NCT ID: NCT02220036
Last Updated: 2014-08-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
80 participants
INTERVENTIONAL
2014-06-30
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Low GI/ Glycemic Load (GL) Diet in Diabetic Nephropathy Patients
NCT02384902
Risk of CKD in Diabetic Patients With MAFLD
NCT06304844
Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
NCT00324675
The Differential Effects of Diabetes Therapy on Inflammation
NCT02150707
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
NCT06668753
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Magnesium Oxide
magnesium tablets, 250 milligram magnesium, 12 weeks, every day 1 tablet
Magnesium Oxide
Patients aged more than 18 years old with diabetic nephropathy having Fasting Blood Sugar more than 126 mg/dL and proteinuria 30-300 mg/dL (microalbuminuria) and Glomerular Filtration Rate more than 90 mL/min will be chosen. Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 12 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic, renal and inflammatory profiles will be measured at the beginning and end of the study as well as anthropometric measurements.
Placebo
Placebo tablets, the same in color, odor and appearance with magnesium tablets, 12 weeks, one tablet every day
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Magnesium Oxide
Patients aged more than 18 years old with diabetic nephropathy having Fasting Blood Sugar more than 126 mg/dL and proteinuria 30-300 mg/dL (microalbuminuria) and Glomerular Filtration Rate more than 90 mL/min will be chosen. Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 12 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic, renal and inflammatory profiles will be measured at the beginning and end of the study as well as anthropometric measurements.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diabetic nephropathy
* Fasting Blood Sugar more than 126 milligram per deciliter
* Proteinuria 30-300 milligram per deciliter (microalbuminuria)
* Glomerular Filtration Rate more than 90 milliliter per minute
* Not having hyperthyroidism or hypothyroidism
* Not having any feverish urinary tract infection
* Not using any kind of drug including Cigarette
* Not having any liver disease
* Not having any cancer and inflammatory diseases
* Not having more than 4 kilogram weight loss during last 3 months
* Not using any magnesium-rich supplement
Exclusion Criteria
* Not having adherence (using less than 75 percent of medicines)
* Cardiac Arrhythmias
9 Months
12 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Isfahan University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Leila Azadbakht
Effect of Magnesium Supplementation on Kidney Function, Insulin Resistance and Metabolic Profile in Patients With Diabetic Nephropathy
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmad Sadeghian, Professor
Role: STUDY_CHAIR
Isfahan University of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Isfahan University of Medical Sciences
Isfahan, Isfahan, Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
198476
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.